article thumbnail

First FDA pregnancy-approved Pertussis vaccine to protect newborns

European Pharmaceutical Review

The US Food and Drug Administration (FDA) has approved GlaxoSmithKline Biologicals’ Boostrix vaccine for use in pregnant woman in their third trimester, to prevent against whooping cough (pertussis) in infants up to two months of age. Since 2012, the CDC has recommended the vaccine series during the third trimester of each pregnancy.

Vaccines 105
article thumbnail

US FDA approves GSK’s pertussis vaccine to protect newborn

Pharmaceutical Technology

The US Food and Drug Administration (FDA) has approved GlaxoSmithKline ’s (GSK) Boostrix (tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine adsorbed [Tdap]) for pregnant women during their third trimester to prevent pertussis (whooping cough) in newborn infants.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

The imperative of fridge-free vaccines

European Pharmaceutical Review

Many of today’s vaccines are produced in ready-to-inject liquid formulations that must be kept cold to maintain stability. However, this greatly complicates both the worldwide distribution and stockpiling of vaccines and other drugs. A requisite cold chain has been designed and implemented to be uninterrupted from factory to patient.

Vaccines 111
article thumbnail

STAT+: Report: Tuberculosis R&D funding is up, but still short of goals and dominated by a few players

STAT

Specifically, the amount spent on basic research, new treatments, vaccines, and diagnostics was $1.2 billion, the highest level since tracking of funding began in 2005 and 20% more than what was seen in 2022.

article thumbnail

UK biotech ‘booming’ as sector rakes in £1.6bn in Q2 financing

pharmaphorum

The new figures – from the BioIndustry Association and Clarivate – were dominated by more than £1 billion in venture capital funding for UK biotech and life sciences companies, headlined by DNA sequencing company Oxford Nanopore’s £195 million raise in May that was just shy of the £205 million record set by Immunocore in 2005.

article thumbnail

Breaking through the forecasting fog – 3 trends that will impact critical medicine supply in 2023

pharmaphorum

The recent reversal of China’s “zero Covid” policy, at a time when the country still lacks optimal vaccine coverage, has also created another unknown, in terms of global supply and demand forecasting. He previously held regional leadership roles at Sandoz between 2005 and 2010.

Packaging 105
article thumbnail

A history of AstraZeneca

pharmaphorum

Between 2001 and 2005, Nexium netted AstraZeneca approximately $14.4 AstraZeneca’s first acquisition following its creation was of KuDOS Pharmaceuticals, a UK biotech company, for £120 million in 2005. In June 2007, AstraZeneca completed the acquisition of vaccine maker MedImmune, buying its drug-development pipeline for $15.2

Vaccines 116